MECOM and B-cell chronic lymphocytic leukemia: TCL1A and MECOM showed a strong interactive clinical hazard prediction in prospectively treated patients, suggesting a contribution of the described regulatory circuit to an aggressive cellular and clinical phenotype in CLL [29].